Cowen & Company Initiates Nexvet Biopharma With Outperform
Analysts at Cowen & Company initiated coverage on Nexvet Biopharma Public Limited Company (NASDAQ: NVET) with a Outperform rating.
The target price for Nexvet Biopharma is set to $15.
Nexvet Biopharma's shares fell 0.69% to close at $10.10 yesterday.
Latest Ratings for NVET
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 2017 | Credit Suisse | Downgrades | Overweight | Equal-Weight |
| Feb 2016 | Credit Suisse | Initiates Coverage On | Outperform | |
| Mar 2015 | Cowen & Co. | Initiates Coverage On | Outperform |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Cowen & CompanyInitiation Analyst Ratings
